Insmed (NASDAQ:INSM) Issues Quarterly Earnings Results, Beats Expectations By $0.61 EPS

Insmed (NASDAQ:INSM) released its earnings results on Thursday. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.61, FiscalAI reports. Insmed had a negative net margin of 76.94% and a negative return on equity of 122.43%. The business had revenue of $425.49 million during the quarter, compared to the consensus estimate of $395.50 million. During the same quarter in the prior year, the firm posted ($1.70) EPS. The company’s revenue for the quarter was up 296.1% compared to the same quarter last year.

Here are the key takeaways from Insmed’s conference call:

• BRINSUPRI launch momentum accelerated: Second-quarter revenue reached $309.2 million, up 49% sequentially, with approximately 7,000 new patient starts and more than 6,300 cumulative prescribers. Insmed raised 2026 BRINSUPRI revenue guidance to $1.25 billion–$1.4 billion from above $1 billion.
• Insmed increased its estimated global peak sales opportunity for BRINSUPRI to more than $7 billion, citing expanding diagnosis, strong persistence and payer access, and the potential for broader use among patients with comorbid COPD or asthma. The company said prescribing depth and refill behavior are tracking at or ahead of internal expectations.
• TPIP data strengthened the company’s confidence in its pipeline centerpiece. In a 12-month PAH open-label extension, patients maintained or improved efficacy measures, 65% reached refined low-risk status, treatment continuation was 91%, and no new safety signals emerged; Phase III programs in PAH and PH-ILD are enrolling, with PPF and IPF studies planned.
• ARIKAYCE revenue rose 8% year over year to $116.3 million, while Insmed reiterated 2026 guidance of $450 million–$470 million. The company has submitted for a U.S. label expansion into newly diagnosed MAC lung disease and expects a Japanese submission in the second half of 2026, potentially supporting launches in 2027.
• Insmed reported approximately $1.2 billion in cash and reiterated expectations for cash-flow positivity in 2027 without additional capital raises, despite planned investment in TPIP Phase III trials, BRINSUPRI advertising, and Japanese commercial infrastructure. Management also noted that European commercialization is less attractive because of budget constraints and limited willingness to pay for innovation.

Insmed Trading Down 1.1%

Shares of Insmed stock traded down $1.45 on Friday, reaching $131.10. 4,904,073 shares of the company’s stock were exchanged, compared to its average volume of 3,072,772. The company has a market capitalization of $28.42 billion, a P/E ratio of -31.90 and a beta of 0.81. Insmed has a 52 week low of $90.39 and a 52 week high of $212.75. The firm’s 50-day moving average is $105.14 and its two-hundred day moving average is $129.23. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47.

Insider Activity at Insmed

In related news, CEO William Lewis sold 10,699 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $117.40, for a total transaction of $1,256,062.60. Following the transaction, the chief executive officer directly owned 259,058 shares of the company’s stock, valued at $30,413,409.20. This represents a 3.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 2,370 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total transaction of $242,379.90. Following the completion of the sale, the chief operating officer owned 98,603 shares of the company’s stock, valued at $10,084,128.81. The trade was a 2.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 54,590 shares of company stock worth $5,793,738. Corporate insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Insmed

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. CIBC Private Wealth Group LLC lifted its stake in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the last quarter. Transamerica Financial Advisors LLC increased its holdings in shares of Insmed by 72.3% in the fourth quarter. Transamerica Financial Advisors LLC now owns 348 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 146 shares during the period. Brooklyn Investment Group lifted its stake in shares of Insmed by 5.7% in the 4th quarter. Brooklyn Investment Group now owns 2,839 shares of the biopharmaceutical company’s stock valued at $501,000 after acquiring an additional 152 shares during the last quarter. Raiffeisen Bank International AG purchased a new stake in Insmed during the 4th quarter valued at about $32,000. Finally, Insigneo Advisory Services LLC grew its position in Insmed by 10.2% during the 4th quarter. Insigneo Advisory Services LLC now owns 2,641 shares of the biopharmaceutical company’s stock worth $460,000 after acquiring an additional 245 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on INSM. Mizuho set a $192.00 price target on shares of Insmed in a research report on Tuesday, June 16th. BMO Capital Markets began coverage on shares of Insmed in a research report on Monday, July 20th. They set an “outperform” rating and a $192.00 price objective for the company. Guggenheim lowered their target price on shares of Insmed from $207.00 to $205.00 and set a “buy” rating for the company in a research note on Friday. Evercore restated an “outperform” rating and issued a $170.00 target price on shares of Insmed in a report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $220.00 price target on shares of Insmed in a research report on Monday, July 20th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $205.26.

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: BRINSUPRI sales significantly exceeded expectations. Second-quarter revenue reached $309.2 million, up 49% from the first quarter, reflecting strong commercial uptake of the company’s bronchiectasis treatment. Insmed raised 2026 BRINSUPRI revenue guidance to $1.25 billion-$1.40 billion and increased its peak-sales estimate to more than $7 billion. Insmed Second-Quarter 2026 Results
• Positive Sentiment: Insmed beat quarterly estimates. Total revenue was $425.5 million, up 296.1% year over year and above the approximately $393.7 million consensus forecast. The company reported a loss of $0.06 per share, substantially narrower than the expected $0.67 loss and the $1.70 loss recorded a year earlier. Insmed Tops Q2 Earnings Estimates
• Positive Sentiment: Long-term growth expectations improved. Insmed lifted its combined peak-revenue outlook for BRINSUPRI, TPIP and ARIKAYCE to more than $14 billion, including over $6 billion for TPIP. It maintained 2026 ARIKAYCE revenue guidance of $450 million-$470 million and provided total 2026 revenue guidance of approximately $1.7 billion-$1.9 billion.
• Positive Sentiment: Trading activity signaled strong investor interest. Call-option volume rose roughly 469% above average, while reports described the stock as gaining about 30%-34% following the earnings release. Analysts also maintained an overall “Buy” recommendation.
• Neutral Sentiment: Profitability remains limited. Despite the improved loss, Insmed continues to report negative net income and return on equity as it invests in developing and commercializing its pipeline.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.